Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ephedra-associated cardiomyopathy.

Sarjita D Naik1, Ronald S Freudenberger

  • 1Department of Pharmacy, Robert Wood Johnson University Hospital, New Brunswick, NJ 08903-2601, USA. sarjita.naik@rwjuh.edu

The Annals of Pharmacotherapy
|January 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low-Level Viraemia.

Alimentary pharmacology & therapeutics·2026
Same author

Hepatitis B Virus Treatment Gaps in the US.

JAMA network open·2025
Same author

Cognitive Decline Over Time in Patients With Systolic Heart Failure: Insights From WARCEF.

JACC. Heart failure·2019
Same author

Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.

ESC heart failure·2019
Same author

Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction.

European journal of clinical investigation·2019
Same author

Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).

The American journal of cardiology·2018

Dietary supplements containing ephedra (a sympathomimetic agent) were linked to two cases of cardiomyopathy in young men. These findings highlight potential cardiovascular risks associated with ephedra use.

Area of Science:

  • Cardiology
  • Toxicology
  • Pharmacology

Background:

  • Dietary supplements containing ephedra are widely available.
  • Ephedra contains ephedrine, a potent sympathomimetic agent.
  • Sympathomimetic agents can cause significant cardiovascular effects.

Observation:

  • Two young men presented with symptoms of heart failure and chest pain.
  • Cardiac evaluations revealed dilated cardiomyopathy with global hypokinesis.
  • One patient died due to heart failure complications weeks after initial presentation.

Findings:

  • An objective causality assessment suggested a possible link between ephedra use and cardiomyopathy.
  • Ephedrine's sympathomimetic effects can lead to myocyte toxicity.
  • Cardiovascular toxicities associated with ephedra include myocarditis, arrhythmias, and sudden death.

Related Experiment Videos

Implications:

  • Healthcare providers should be aware of the potential cardiovascular risks of ephedra-containing supplements.
  • Patients should be educated about the dangers of using such products.
  • Further research is warranted to understand the mechanisms and prevalence of ephedra-induced cardiomyopathy.